Effects of 2-alkynyladenosine derivatives on intraocular pressure in rabbits

European Journal of Pharmacology

Volumn 486, Issue 3, 2004, Pages 307-316

  Konno, Takashi ^a   Ohnuma, Shin Ya ^a   Uemoto, Kazuhiro ^a   Uchibori, Takehiro ^a   Nagai, Akihiko ^a   Kogi, Kentaro ^a   Endo, Kazuki ^b   Hosokawa, Tomokazu ^c   Nakahata, Norimichi ^d  

^a TOA EIYO LTD   (Japan)

^b YAMASA CORPORATION   (Japan)

^c HOSHI UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

2 Alkynyladenosine derivative; Adenosine A2 receptor; Intraocular pressure; Outflow facility

Indexed keywords

2 (1 BUTYN 1 YL)ADENOSINE; 2 (1 HEPTYN 1 YL)ADENOSINE; 2 (1 HEXYN 1 YL)ADENOSINE; 2 (1 PENTYN 1 YL)ADENOSINE; 2 (2 CYCLOHEXYL 1 ETHYN 1 YL)ADENOSINE; 2 (3 BUTOXY 1 PROPYN 1 YL)ADENOSINE; 2 (3 CYCLOHEXYL 1 PROPYN 1 YL)ADENOSINE; 2 (3 HYDROXY 1 BUTYN 1 YL)ADENOSINE; 2 (3 HYDROXY 1 PROPYN 1 YL)ADENOSINE; 2 (3 HYDROXY 3 METHYL 1 BUTYN 1 YL)ADENOSINE; 2 (3 METHOXY 1 PROPYN 1 YL)ADENOSINE; 2 (4 CYCLOHEXYL 1 BUTYN 1 YL)ADENOSINE; 2 (4 OCTOXY 1 BUTYN 1 YL)ADENOSINE; 2 (4 PROPOXY 1 BUTYN 1 YL)ADENOSINE; 2 (5 ETHOXY 1 PENTYN 1 YL)ADENOSINE; 2 (6 CYANO 1 HEXYN 1 YL)ADENOSINE; 2 (OCTYN 1 YL)ADENOSINE; 2 ANILINOADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3,7 DIMETHYL 1 PROPARGYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; CHYMOTRYPSIN A; HYPERTENSIVE AGENT; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SCREENING; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 1242314692     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.12.034     Document Type: Article

References (29)

1. 2 receptor agonists. Jpn. J. Pharmacol. 52(Suppl. II):1990;92.
2. 2 receptors. Eur. J. Pharmacol. 196:1991;69-76.
3. 2 receptor agonists with potent antihypertensive effects. J. Med. Chem. 35:1992;2253-2260.
4. Chiang C.H., Lin C.H. Effects of cromakalim and nicorandil on intraocular pressure after topical administration in rabbit eyes. J. Ocular Pharmacol. Ther. 11:1995;195-201.
5. Crosson C.E. Ocular hypotensive activity of the adenosine agonist (R)-phenylisopropyladenosine in rabbits. Curr. Eye Res. 11:1992;453-458.
6. Crosson C.E. Adenosine receptor activation modulates intraocular pressure in rabbits. J. Pharmacol. Exp. Ther. 273:1995;320-326.
7. Crosson C.E., Gray T. Modulation of intraocular pressure by adenosine agonists. J. Ocul. Pharmacol. 10:1994;379-383.
8. Crosson C.E., Gray T. Characterization of ocular hypertension induced by adenosine agonists. Investig. Ophthalmol. Vis. Sci. 37:1996;1833-1839.
9. Crosson C.E., Petrovich M. Contributions of adenosine receptor activation to the ocular actions of epinephrine. Investig. Ophthalmol. Vis. Sci. 40:1999;2054-2061.
10. 2 on the aqueous humor dynamics in rabbits. Graefe Arch. Clin. Exp. Ophthalmol. 227:1989;476-481.
11. + channels. Zhongguo Yaoli Xuebao. 20:1999;257-261.
12. 2 adenosine receptor agonists with potent antihypertensive activity. J. Med. Chem. 35:1992;2881-2890.
13. Kvanta A., Seregard S., Sejersen S., Kull B., Fredholm B.B. Localization of adenosine receptor messenger RNAs in the rat eye. Exp. Eye Res. 65:1997;595-602.
14. Langham M.E., Leydhecker W., Krieglstein G., Waller W. Pneumatonographic studies on normal and glaucomatous eyes. Adv. Ophthalmol. 32:1976;108-133.
15. Matsuda A., Ueda T. The synthesis, mutagenic and pharmacological activities of 2-carbon-substituted adenosines. Nucleosides Nucleotides. 6:1987;85-94.
16. Matsuda A., Shinozaki M., Miyasaka T., Machida H., Abiru T. Palladium-catalyzed cross-coupling of 2-iodoadenosine with terminal alkynes: synthesis and biological activities of 2-alkynyladenosines. Chem. Pharm. Bull. 33:1985;1766-1769.
17. 2 receptor agonists with potent antihypertensive effects. J. Med. Chem. 35:1992;241-252.
18. Pang I.H., Shade D.L., Clark A.F., Steely H.T., DeSantis L. Preliminary characterization of a transformed cell strain derived from human trabecular meshwork. Curr. Eye Res. 13:1994;51-63.
19. Quayle J.M., Standen N.B. KATP channels in vascular smooth muscle. Cardiovasc. Res. 28:1994;797-804.
20. Sears D., Sears M. Blood-aqueous barrier and alpha-chymotrypsin glaucoma in rabbits. Am. J. Ophthalmol. 77:1974;378-383.
21. Sharif N.A., Xu S.X., Crider J.Y., McLaughlin M., Davis T.L. Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J. Ocular Pharmacol. Ther. 17:2001;305-317.
22. Sonntag J.R., Brindley G.O., Shields M.B. Effect of timolol therapy on outflow facility. Investig. Ophthalmol. Vis. Sci. 17:1978;293-296.
23. Sugrue M.F. New approaches to antiglaucoma therapy. J. Med. Chem. 40:1997;2793-2809.
24. Thorpe R.M., Kolker A.E. A tonographic study of water loading in rabbits. Arch. Ophthalmol. 77:1967;238-243.
25. Watanabe A., Hosokawa T., Misawa M. Studies on ocular pharmacology (Rept. 29): role of adenosine receptors in regulation of intraocular pressure in albino rabbits. Jpn. J. Pharmacol. 79(Suppl. I):1999;127.
26. Watanabe A., Hosokawa T., Misawa M. Studies on ocular pharmacology (Rept. 33): involvement of NO and potassium channel in responses in albino rabbits. Jpn. J. Pharmacol. 82(Suppl. I):2000;123.
27. 2 receptor agonist, involve the opening of glibenclamide-sensitive K+ channels. Eur. J. Pharmacol. 213:1992;199-204.
28. 2α. Clin. Rep. 28:1994;3827-3838.
29. Zhang X., Wang N., Schroeder A., Erickson K.A. Expression of adenylate cyclase subtypes II and IV in the human outflow pathway. Investig. Ophthalmol. Vis. Sci. 41:2000;998-1005.